Agendia (Netherlands)

Recent papers from Agendia (Netherlands)

1. Parents’ Experiences and Perceived Benefits of a Parent Program in Pediatric Type 1 DiabetesJournal of Family Nursing · 2026
2. Treatment burden and health‐related quality of life in young adults with type 1 diabetesDiabetic Medicine · 2026
3. Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX StudyJCO Precision Oncology · 2026
4. Association of the 70-gene assay and homologous recombination deficiency in patients with high risk 2 breast cancers.Journal of Clinical Oncology · 2026
5. Opinion Leadership among Nurses in Public Debate: Moral Conviction, Credibility, and Collective SupportPolicy Politics & Nursing Practice · 2026
6. Whole transcriptome analysis reveals MammaPrint and BluePrint-associated gene expression patterns with early lymph node metastasis in early-stage breast cancerBreast Cancer Research and Treatment · 2026
7. Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancernpj Breast Cancer · 2026
8. Abstract PS4-09-09: Distinct Immune and Metabolic profiles in Latin American breast cancer patients with obesity enrolled in FLEXClinical Cancer Research · 2026
9. Abstract PS3-08-17: HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene signature benefit from (Neo)adjuvant chemotherapy (CT): Real World FLEX StudyClinical Cancer Research · 2026
10. Abstract PS2-07-03: Improved 3-year IDFS with anthracycline-based therapy for patients with 70-gene signature High 2, Luminal B, HR+HER2- early-stage breast cancerClinical Cancer Research · 2026
11. PS5-09-19: Flex: from genomic profiling to real-world insights in 30,000 patients with early-stage breast cancerClinical Cancer Research · 2026
12. Picture living with diabetes: A photovoice study of young adults' efforts in making diabetes care fit into their livesDiabetic Medicine · 2026
13. Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101)European Journal of Cancer · 2025
14. Bifunctional Phagocytic Synapse Enhancers for Cancer Immunotherapy2025
15. Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinomaAmerican Journal of Clinical Pathology · 2025
16. MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry AnalysisEMJ Oncology · 2024
17. Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patientsHeliyon · 2024
18. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.Journal of Clinical Oncology · 2024
19. Cost consequence model of the MammaPrint (70-gene signature) and 21-gene signature in patients with primary HR+HER2-, N1 early-stage breast cancer in Germany.Journal of Clinical Oncology · 2024
20. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub studyCancer Research · 2024